Blog
RSS FeedPosted by Michael Wonder on 28 Sep 2022
News “hyperbole” in Government media releases on new drugs can undermine confidence in NHS, says editor
28 September 2022 - Phrases such as “cutting edge,” “game changing,” and “ground breaking” have no place in the description ...
Posted by Michael Wonder on 28 Sep 2022
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
28 September 2022 - NICE has published evidence-based recommendations on the use of atezolizumab for adjuvant treatment of adults with ...
Posted by Michael Wonder on 23 Sep 2022
1,500 people set to receive new skin cancer treatment that reduces the risk of it returning and spreading
23 September 2022 - Around 1,500 people aged 12 years and over with melanoma are set to benefit from pembrolizumab (also ...
Posted by Michael Wonder on 23 Sep 2022
NICE approves routine use of drug combination for advanced breast cancer
23 September 2022 - Another life-extending drug combination for some people with advanced breast cancer will now be available for routine ...
Posted by Michael Wonder on 23 Sep 2022
Vedolizumab for the treatment of patients with chronic refractory pouchitis
21 September 2022 - NICE is unable to make a recommendation about the use in the NHS of vedolizumab for the ...
Posted by Michael Wonder on 20 Sep 2022
NICE recommends BeiGene’s Brukinsa (zanubrutinib) for patients with Waldenström’s macroglobulinaemia who have had at least one treatment
19 September 2022 - Brukinsa Is the first Bruton’s tyrosine kinase inhibitor recommended by NICE for routine use for Waldenström’s macroglobulinaemia. ...
Posted by Michael Wonder on 15 Sep 2022
Advicenne updates on availability of Sibnayal to patients and caregivers in Great Britain
14 September 2022 - Sibnayal has been accepted for use within NHS Scotland. ...
Posted by Michael Wonder on 14 Sep 2022
Dexamethasone intravitreal implant for treating diabetic macular oedema
14 September 2022 - NICE has published evidence-based recommendations on the use of dexamethasone intravitreal implant for the treatment of ...
Posted by Michael Wonder on 14 Sep 2022
NICE inks another early full stop on the appraisal of a cancer medicine
14 September 2022 - Once again, the sponsor decided not to provide an evidence submission. ...
Posted by Michael Wonder on 08 Sep 2022
Esketamine: NICE’s appraisal was unfair, appeal panel rules
8 September 2022 - The decision by the UK National Institute for Health and Care Excellence not to recommend esketamine ...
Posted by Michael Wonder on 06 Sep 2022
Bristol Myers Squibb’s acute myeloid leukaemia oral maintenance therapy recommended by NICE
6 September 2022 - Phase 3 trial results show Onureg offers significantly longer overall and relapse-free survival. ...
Posted by Michael Wonder on 06 Sep 2022
ICR criticises NICE rejection of olaparib for advanced prostate cancer
6 September 2022 - The Institute of Cancer Research, London, has expressed disappointment that NICE has confirmed its decision not ...
Posted by Michael Wonder on 31 Aug 2022
Brolucizumab for treating diabetic macular oedema
31 August 2022 - NICE has published evidence-based recommendations on the use of brolucizumab (Beovu) for the treatment of adults ...
Posted by Michael Wonder on 24 Aug 2022
Avalglucosidase alfa for treating Pompe disease
24 August 2022 - NICE has published evidence-based recommendations on the use of avalglucosidase alfa for the treatment of patients ...
Posted by Michael Wonder on 18 Aug 2022
CSL Vifor plans UK launch after NICE backs rare disease drug Tavneos
18 August 2022 - UK cost-effectiveness organisation NICE has recommended routine NHS use of a recently approved therapy for two ...